Mouth ulceration

1. Everolimus raises the risk of mouth ulceration in humans (32% vs 5%).

   Human trialtuberous sclerosis complex4.5 mg/m2 per dayn = 117

   Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

   Lancet (London, England)·14 Nov 2012

More on Everolimus